However, caregivers are not allowed to seek out relatives at risk but can encourage diagnosed patients to ask their relatives to be screened for FH. But this way of manually linking large groups of people to healthcare, possibly across healthcare regions, is a resource and time-consuming task. Although initiatives are made, systematic screening has not been a part of routine care.
- FH is a disease that is well suited for digiphysical cascade screening, and with FHabian we have developed an effective and time-saving process to increase the possibility to find undiagnosed individuals, says Karin Littmann.
FHabian is an innovation project in the Stockholm region, a collaboration between Karolinska University Hospital, Health Solutions and Amgen.
- This is a completely new approach to screening and the collaborative approach to this project has been essential to make it successful. Each partner has brought important perspectives, all necessary to make a tool that is easy to use for both patients and caregivers. And the response from patients has been very positive, says Jonas Brinck, MD, PhD and senior consultant in endocrinology at Karolinska University Hospital.
One important aspect of the project is that FHabian enables seamless screening and testing across healthcare regions. The screening tool is up and running since February 2021 in the Stockholm Region, with plans to extend the service with pilots in other regions during 2021. You can find more information about FHabian here